knowledge -WSS

knowledge

author：entertainment 2025-08-23 08:56:40 - browse：6

U.S. legislation that would sever ties with Chinese drugmakers would jeopardize the drug supply for millions of American patients if it’s passed, the biotechnology industry’s main trade group has told Congress.

Congress is considering legislation, called the BIOSECURE Act, that would make it difficult for Chinese contract development and manufacturing organizations to do business with biotechnology companies that work with the U.S. federal government. Biotechs hire Chinese CDMOs, as they’re often called, for services that include product manufacturing, development, formulation, packaging, and distribution.

The BIOSECURE Act would stop the federal government from contracting with, or providing grants to, companies that do business with so-called Chinese “companies of concern.” The impact of the legislation would depend in large part on who is in the White House. The White House’s Office of Management and Budget would determine which companies are blacklisted, but a handful of specific companies would automatically go on that list, including the biotech giant WuXi AppTec.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Telehealth startups turn to complex chronic diseases

WSS

Shionogi licenses Pompe disease therapy from Maze Therapeutics

Study: People of West African ancestry at greater risk of cardiac amyloidosis

White House announces new plan to address the growing threat of xylazine in overdose crisis

Readout Newsletter: Sanofi, Novavax, Maze x Shionogi news

US sending controversial cluster munitions to Ukraine until other ammo is ready: Kirby

H5N1 bird flu: what we're starting to learn about infection in cows

entertainment

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Wikipedia

Wildfire smoke exposes gaps in outdoor worker protections

Study: AI not yet building 'n

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Recent heat wave in the Mediterranean caused by climate change: Study

Moonlake's readout produced a cash windfall. Risks remain

Use wet bulb globe temperature, not heat index, to protect workers

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Create a giant ice tray with this foil pan hack to keep food cold this summer

Trump demands the U.S. pay no more for drugs than other countries … again

Nevada Republican Sam Brown launching another Senate bid, teeing up marquee race

knowledge

White House announces new plan to address the growing threat of xylazine in overdose crisis

It shouldn't be easy to buy synthetic DNA to recreate a deadly virus

The U.S. needs a new definition of substance use “recovery”

First recipient of genetically engineered pig kidney has died

Home health providers sue Medicare over payment cuts

Sanofi strikes deal with Novavax, boosting the vaccine maker

explore

focus

entertainment

Wikipedia